ponesimod (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Multiple Sclerosis

Pending FDA approval for treatment of adult patients with relapsing multiple sclerosis (MS)

Next:

Pharmacology

Mechanism of Action

Selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator

Binds with high affinity to S1P receptors; blocks lymphocyte egress from lymph nodes

Mechanism by which ponesimod exerts therapeutic effects in MS is unknown, but may involve reduction of lymphocyte migration into the central nervous system and damage to myelin

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.